Home Blog Page 1952

IFS’ State of Service 2025 Report Reveals Manufacturing’s Shift from Products to Service-Driven Growth

By
Advertorial Desk
-

LONDON, Oct. 16, 2025 /PRNewswire/ — IFS, the leading provider of Industrial AI software, has released a global study showing how Industrial AI, among other trends, is reshaping the manufacturing sector. The State of Service 2025: Manufacturing Transformation Report, produced with Accenture, finds that service is no longer a support function but a strategic profit engine, with 39% of respondents citing servitization as central to long-term growth. Based on insights from 800 senior manufacturing leaders, the report highlights that Industrial AI, servitization, and sustainability are transforming how manufacturers compete, operate, and deliver value and that manufacturers must act soon to take advantage of the new opportunities.

The research reveals a sector in transition, driven by technological advances and changing customer expectations. While 63% of manufacturers are prioritizing cloud infrastructure and emerging technologies like AI, IoT, and AR for future growth, there’s a notable gap in AI adoption: 96% use AI in service delivery, but nearly three-quarters haven’t scaled it across operations. To stay competitive as service becomes a core growth driver, manufacturers must accelerate their AI integration and modernization efforts.

Mark Moffat, CEO, IFS, said: “Manufacturing is undergoing a defining transformation. Service has evolved from a support function into a core profit engine, with 94% of manufacturers reporting that new service models are already impacting operations. Industrial AI and sustainability are now central to delivering smarter, faster, and more personalized service.”

Gert Müller, EMEA Intelligent Asset Management Lead, Accenture, said: “Manufacturing today is about innovating faster, optimizing smarter, and delivering service with intelligence at every touchpoint. Service has reached a tipping point: it is no longer a support function but the front line of competitive advantage. With Industrial AI maturing rapidly, manufacturers can anticipate needs, personalize experiences, and extend service value like never before.”

Industrial AI moves from pilot to scale
While 28% of manufacturers have fully scaled AI, many are still struggling with barriers like data quality governance, cybersecurity and data privacy concerns, or integration challenges with legacy systems. Focusing on removing these key blockers is crucial to fully realizing the value of AI in optimizing operations and driving predictive, real-time decision-making.

Reskilling the Workforce for a Service-Led Future
As manufacturers shift from traditional break-fix and warranty models to outcomes-based contracts and tiered service offerings, the workforce must evolve in parallel. With 98% of manufacturers reporting labor shortages, the pressure to build internal capability is intensifying. In response, companies are adopting forward-looking strategies such as internal training academies, e-learning platforms, academic partnerships, and selective automation. These initiatives are not just about filling gaps—they’re about equipping teams with the skills needed to thrive in a digitally enabled, service-centric environment.

Sustainability and circular economy
Sustainability is now a strategic priority for 97% of manufacturers, with 79% tracking emissions from service activity and 37% doing so in real time. Companies are embedding circular economy practices including refurbished components, route optimization, and predictive maintenance to cut waste and extend asset lifecycles.

Resilience under pressure
Supply chain disruption remains a challenge, affecting 95% of respondents over the past year. Yet confidence in resilience is mixed: only 32% feel ‘very confident’, highlighting ongoing opportunities to strengthen planning, scenario modeling, and local sourcing strategies.

The report underscores that while manufacturers are moving fast to modernize service, there is still significant room for growth. Those that successfully scale AI, embed new service models, and address workforce and sustainability challenges will define the next era of industrial competitiveness.

To see how your organization compares and explore the full findings, download the full report. 

IFS Press Contacts:

EUROPE / MEA / APJ: Adam Gillbe
IFS, Director of Corporate & Executive Communications
Email: adam.gillbe@ifs.com

NORTH AMERICA / LATAM: Mairi Morgan
IFS, Director of Corporate & Executive Communications
Email: mairi.morgan@ifs.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

 

NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities

By
Advertorial Desk
-

NEW YORK, Oct. 16, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.

 

NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities

Ashley Mastronardi delivers the pre-market update on October 16th

  • Stocks are fractionally higher Thursday morning after the S&P 500 ended Wednesday in the green. NYSE-listed Bank of America and Morgan Stanley increased share price by over 4% following their latest earnings report.
  • NYSE-listed HPE rang the Opening Bell yesterday to celebrate its 10th anniversary and to highlight its 2025 HPE Securities Analyst Meeting. There, they discussed plans to boost shareholder value through stronger growth and returns.
  • Front Office Sports and DealMaker are hosting the first ever Asset Class event at the NYSE today. It will include panels on ownership and discussions about the new era of sports investing.

Opening Bell
Susan G. Komen celebrates National Breast Cancer Awareness Month, honoring patients and survivors across the country.

Closing Bell
Front Office Sports celebrates its inaugural Asset Class event presented by DealMaker.

Click here to download the NYSE TV App

 

Cell Publishes Breakthrough Research Results of IASO Bio’s Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

By
Advertorial Desk
-

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the Cell published results from the study evaluating its independently developed fully human anti-BCMA CAR-T cell therapy, Equecabtagene Autoleucel (Eque-cel), for the treatment of progressive multiple sclerosis (PMS). This landmark study provides the world’s first clinical evidence confirming the safety and efficacy of a CAR-T therapy in PMS. It is also the first paper Cell has ever published on the successful application of BCMA-targeted CAR-T therapy for an autoimmune disease, representing a pivotal advancement in this field.

The study entitled ‘Anti-BCMA CAR-T Cells in Progressive Multiple Sclerosis’ has been published in Cell. Full text available at: www.cell.com/cell/fulltext/S0092-8674(25)01088-8. This study is based on an investigator-initiated trial (NCT04561557) led by Professor Wei Wang’s team from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

This study enrolled five patients with PMS，including 1 with primary progressive MS (PPMS) and 4 with secondary progressive MS (SPMS), with a mean age at disease onset of 38.2 years and a baseline mean Expanded Disability Status Scale (EDSS) score of 6.2. Following a single infusion of Eque-cel, the following outcomes were observed:

Significant efficacy: All five patients demonstrated significant improvements in EDSS scores, Nine-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) tests. Complete disappearance of cerebrospinal fluid oligoclonal bands (OCBs) and significant decrease in kappa free light chain (κFLC) levels were observed. Follow-up MRI scans revealed no new T1 gadolinium-enhancing lesions or new/enlarging T2 lesions.

Manageable safety profile: Only transient grade 1 cytokine release syndrome (CRS) occurred in 80% of patients, with no cases of ≥grade 2 CRS. No immune effector cell-associated neurotoxicity syndrome (ICANS) or other neurotoxic reactions were observed.

Professor Wei Wang from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, the principal investigator of this study, stated: “We are delighted to see our team’s research published in Cell, a significant milestone in the field of cell therapy. Our work has pioneered the application of anti-BCMA CAR-T therapy for multiple sclerosis and other refractory neuroimmune diseases, providing the world’s first clinical validation of both its safety and efficacy in patients with progressive MS. Notably, 83% of the refractory patients achieved long-term clinical remission without requiring ongoing medication. This study not only challenges the existing treatment paradigm but also reveals novel regulatory mechanisms within the central nervous system immune microenvironment, paving new directions for immunotherapy in chronic neuroinflammatory diseases.

Building on the remarkable efficacy of Eque-cel in clearing plasma cells and B cells, we are actively expanding the application of this therapy to a broader range of autoimmune diseases, including neuromyelitis optica spectrum disorders and myasthenia gravis, where we have already observed encouraging clinical outcomes. We are optimistic that this CAR-T therapy will offer a novel and powerful treatment option for more patients suffering from autoimmune diseases.”

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Biotherapeutics, stated: “We are delighted that the research findings of Eque-cel for treating MS was published in Cell, one of the world’s most premier scientific journals, and congratulations to Professor Wei Wang and his team as the principal investigators for this accomplishment. This achievement further highlights IASO Bio’s pioneering innovation capabilities in the field of CAR-T cell therapy.

Autoimmune diseases are the key therapeutic focus for IASO Bio. Currently, Eque-cel has obtained multiple clinical trial approvals for autoimmune indications in both China and the U.S., including multiple sclerosis, myasthenia gravis, systemic lupus erythematosus and other autoimmune disorders. Moving forward, we remain committed to driving breakthroughs in autoimmune disease treatment through innovation, with the goal of delivering more advanced therapeutic options to patients worldwide.”

About Multiple Sclerosis

Multiple sclerosis (MS), a neuroinflammatory disease of the central nervous system (CNS) that causes demyelination and neuronal injury, is one of the most common causes of non-traumatic disability among young adults (aged 18–40 years)1. According to Frost & Sullivan Analysis reports, in 2023, about 3.07 million patients suffered from MS worldwide, of which approximately 400 thousand were in the United States and 50 thousand were in China. MS prevalence differs substantially between sexes, with a female to male ratio of 3:12.MS is characterized by focal lymphocytic CNS infiltration leading to myelin destruction and axonal damage, which result in neurologic syndromes and physical disability3. MS clinical manifestations depend on the location of lesions in the CNS. Symptoms may include sensory and visual disturbances; motor and coordination impairment; and spasticity, fatigue, pain, and cognitive deficits4. About 85%–90% of MS patients develop a relapsing-remitting form of the disease, which is characterized by periods of symptom exacerbation followed by remission. As the disease evolves, the recovery from symptoms is incomplete, and around 50% of patients eventually develop a form of the disease known as secondary progressive MS, which is characterized by the progressive, irreversible accumulation of neurologic disability5.

Reference：

1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet 2018; 391: 1622–36.

2. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease

Study 2016. Lancet Neurol 2019;18: 269–85.

3. Compston A, Coles A. 2008. Multiple sclerosis. Lancet 372(9648):1502–17.

4. BDendrou CA, Fugger L, Friese MA. 2015. Immunopathology of multiple sclerosis. Nat.Rev. Immunol.15(9):545–58.

5. Sospedra M, Martin R. 2016. Immunology of multiple sclerosis. Semin. Neurol. 36:115–27.

About Equecabtagene Autoleucel（Eque-cel）

Equecabtagene Autoleucel（Eque-cel）is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, Eque-cel demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses.

 

Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

By
Advertorial Desk
-

SHANGHAI, Oct. 16, 2025 /PRNewswire/ — Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson’s disease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. These data were presented on October 8th at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Honolulu, USA. UX-DA001 is the world’s first autologous cell therapy product for Parkinson’s Disease which has both received clinical trial approval in China and the United States.

The study is led by Principal Investigator Dr. Liu Jun, Professor and Director of the Department of Neurology at Ruijin Hospital Affiliated with School of Medicine, Shanghai Jiao Tong University. The transplantation surgery was performed by Dr. Li Dianyou, Director of the Functional Neurosurgery Department at Ruijin Hospital. Dr. Zhou Liche, a member of  the study team, delivered the presentation, which has been selected as a “Late Breaking” oral platform presentation.

The Phase I clinical trial of UX-DA001 officially commenced  in early 2025. The first patient enrolled in the trial is a female one with moderate-to-severe PD who, despite taking four anti-Parkinson’s medications daily pre-operatively, still experienced significant symptom fluctuations, along with debilitating non-motor symptoms such as sleep disorders and autonomic dysfunction, severely impacting her quality of life.

The 6-month post-treatment data demonstrated a favorable safety profile and significant therapeutic effects for UX-DA001:

  • The patient tolerated the procedure well, with no serious adverse events or adverse events related to the transplanted cells.
  • Significant improvement in motor function: The MDS-UPDRS-III score improved by 21 points during the “OFF-period” and 9 points during the “ON-period”, representing an improvement ratio exceeding 45% in both states.
  • Daily “OFF” time reduced by an average of 3.6 hours, while “ON” time without troublesome dyskinesia increased by 3.3 hours.
  • Non-motor symptoms were alleviated, with early positive improvements were observed in both the NMSS scale and PDQ-39 quality of life scores.
  • 18F-FP-CIT PET imaging showed consecutively increased PET uptake signals in the transplanted bilateral putamen, providing objective evidence for dopamine transporter expression, cell survival and functional integration.

Dr. Zhou Liche commented, “The reduction of Unified Parkinson’s Disease Rating Scale (UPDRS) part III score, indication an improvement in motor function of the first patient, is very encouraging and promising. Furthermore, in addition to the UPDRS scores, which remains the most frequently employed primary endpoint, neuroimaging biomarkers are increasingly recognized as critical outcome measures in PD clinical trials owing to their intrinsic objectivity. In this study, we used 18F-FP-CIT PET to measure the density of presynaptic dopamine transporter. The specific binding ratios (SBR) of 18F-FP-CIT directly mirrors nigrostriatal dopaminergic terminal integrity and serial scans revealed an increasing UX-DA001 graft-derived dopaminergic innervation in putmen. By integrating these imaging readouts with UPDRDS-based clinical scores, the trial achieves a dual-layer assessment—subjective functional status is supported by objective biological evidence. This approach strengthens the validation of clinical findings and accelerates go/no-go decisions for cell therapies in PD.”

“The key advantage of UX-DA001 lies in its technology platforms enabling higher target cell proportion and purity. This allows for achieving comparable efficacy with a lower total number of cells injected, consequently shortening the transplantation procedure time and enhancing its reliability and safety.” Dr. Zhou remarked, in response to a question about the study’s distinctive features compared to other autologous stem cell research.

The Phase I clinical trial for UX-DA001 is still ongoing. Encouraged by the positive results from the first patient, the UniXell Biotech and the clinical team are confident with the promising prospects of the trial. Recognizing that strategic partnerships can accelerate development and expand access to innovative therapies, we welcome discussions with biopharmaceutical companies and investors, both domestically and internationally, who share our vision of providing a new and improved treatment option for Parkinson’s disease patients worldwide.

[About the International Parkinson and Movement Disorder Society (MDS)]

The International Parkinson and Movement Disorder Society(MDS) is the most globally authoritative premier professional organization in the field of Parkinson’s disease and movement disorders. It brings together top-tier international clinical experts, scientists, and healthcare professionals, dedicated to advancing research, clinical care, education, and awareness. The Society was founded in 1985 by Professors Stanley Fahn and C. David Marsden and formally renamed the International Parkinson and Movement Disorder Society in 2013.

About UX-DA001 and Phase 1 Trial

UX-DA001 is an investigational autologous iPSC-derived neural progenitor cell drug. It is derived from the patient’s own peripheral blood cells, which are firstly reprogrammed into induced pluripotent stem cells and then differentiated into dopaminergic neurons in vitro. It is then transplanted into the patient’s brain through a minimally invasive surgery. UX-DA001 leverages the patient’s own cells, significantly reducing the risk of immune rejection. Patients do not require immunosuppressive drugs, thereby avoiding potential side effects such as increased infection and tumor risks, organ toxicity, and metabolic disorders, thus achieving a safer and more effective treatment that significantly improves the quality of life for patients. The UX-DA001 has received clinical trial approvals (Investigational New Drug, IND) from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) in December 2024 and February 2025, respectively, offering UX-DA001 a potential to have implications on patients with Parkinson’s disease in not only China but also globally.

[About UX-DA001]

UX-DA001 is human midbrain dopaminergic neural precursor cells, developed using Unixell‘s proprietary technology platforms: a high-throughput stem cell differentiation lineage tracing platform, a highly efficient neural differentiation platform, and an iPSC reprogramming platform. Leveraging these advanced technologies, the product can generate highly pure, stable, and potent human midbrain dopaminergic neural precursor cells, aiming to effectively repair damaged neural circuits and restore dopamine levels in the brain.

[About Unixell Biotech]

Shanghai Unixell Biotech, founded in 2021, focuses on developing cell therapies for neurological diseases such as Parkinson’s disease and epilepsy. The company operates a 4,000-square-meter R&D center and GMP facility. It has received numerous honors and awards. In December 2024, Unixell‘s UX-DA001 successfully obtained clinical trial approvals from both the National Medical Products Administration (NMPA) of China and the U.S. FDA, making it the first iPSC-derived autologous cell therapy for Parkinson’s disease in China, and the second globally, to enter the clinical stage.

Primech Holdings Signs Strategic MOU with GAIB to Unlock First-of-its-kind ARaaS Revenue Models Through Tokenization

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 16 October 2025 – Primech Holdings Ltd. (“Primech” or the “Company”), a leader in AI-powered hygienic robotics, today announced the signing of a strategic Memorandum of Understanding with GAIB, the economic layer for AI infrastructure. The partnership establishes a framework to tokenize Primech’s HYTRON autonomous cleaning robots and enable next-generation AI Robotics-as-a-Service (ARaaS) business models that open new capital pathways and expand profitability potential.

Under the MOU, GAIB will develop comprehensive protocols to tokenize HYTRON as digital assets, enabling fractional ownership and creating liquid secondary markets for robot investments. The collaboration introduces revolutionary capital solutions by leveraging tokenized assets as collateral for onchain credit facilities, while establishing next-generation ARaaS frameworks that enable automated usage-based payments and continuous revenue generation from robot operations. This tokenization approach transforms traditional robot sales into recurring revenue streams while providing global investors access to AI robotics investments through crypto markets.

The strategic collaboration directly addresses Primech’s capital deployment constraints by unlocking rapid scaling of HYTRON without conventional financing limitations. Asset tokenization creates liquidity premiums for previously illiquid physical equipment, expanding the potential investor base from individual purchasers to thousands of token holders per robotic unit. The blockchain-based infrastructure facilitates international market expansion across multiple networks, enabling Primech to secure global financing and implement transparent, automated payment systems that enhance operational efficiency and reduce transaction costs.

“The partnership with GAIB represents a fundamental breakthrough in realizing the full profit potential of our HYTRON technology,” said Ken Ho, Chairman and CEO of Primech Holdings. “By tokenizing our AI robots, we’re transforming how the robotics industry accesses capital and generates value. Instead of being bounded by traditional financing models, we can now offer fractional robotic ownership to global investors while creating continuous ARaaS revenue streams that multiply the profitability of each HYTRON unit. This alliance positions us to unlock the true economic potential of autonomous hygiene solutions while pioneering new business frameworks that will define the future of AI robotics commercialization.”

Hashtag: #PrimechHoldings #PrimechAI

The issuer is solely responsible for the content of this announcement.

About Primech Holdings Limited

Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit .

About GAIB

GAIB is the economic layer for AI infrastructure, bringing compute and robotic economies onchain. By tokenizing enterprise-grade GPUs and robotics assets with their underlying operational values, GAIB provides capital access for AI infrastructure operators and transparent exposure for participants. Through AID, its AI-backed synthetic dollar, users can engage in the digital AI economy and earn ecosystem rewards via sAID staking. GAIB connects AI infrastructure with decentralized finance—unlocking new opportunities where technology meets capital. For more information, visit .

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

OPPO Find X9 Series to Launch Globally, Set to Redefine Mobile Imaging

By
Advertorial Desk
-

SHENZHEN, CHINA – Media OutReach Newswire – 16 October 2025 – OPPO, the world’s leading smart device brand, today announced the global launch of its latest flagship Find X9 Series following the product’s successful debut in the Chinese market. The launch event will be held in Barcelona on October 28th, 2025, where Find X9 and Find X9 Pro will make their official global debut, setting a new benchmark for mobile photography and flagship smartphone excellence.

OPPO Find X9 Series Global Launch 1

“With Find X Series, OPPO continues to push the boundaries of what’s possible in mobile imaging, uniting industry-leading hardware with state-of-the-art computational photography,” said Pete Lau, SVP and Chief Product Officer at OPPO. “Together with Hasselblad, we are taking a monumental leap forward in imaging quality with Find X9 Series. Combined with a refined design, extraordinary battery life, and the fast and smooth ColorOS 16, Find X9 Series is set to redefine the flagship experience and inspire a new era of creativity with mobile devices.”

Find X9 Series introduces a new-generation design that combines elegance with ergonomic comfort. Find X9 is offered in three color options: Titanium Grey, Space Black, and Velvet Red. Find X9 Pro arrives in two premium finishes, Silk White and Titanium Charcoal. All models feature a refined matte glass finish and matte aluminum frame that enhances both aesthetics and grip.

Complementing this design are two impeccably crafted flat displays. Find X9 features a compact 6.59-inch screen, while Find X9 Pro boasts a larger 6.78-inch immersive display, both of which are framed by ultra-thin 1.15mm symmetrical bezels on four sides.

X9 Pro Titanium Charcoal X9 Titanium Grey X9 Velvet Red

Both Find X9 and Find X9 Pro feature the latest Hasselblad Master Camera System powered by the LUMO Image Engine, OPPO’s in-house computational photography solution. Find X9 Pro pushes boundaries even further with its breakthrough 200MP Hasselblad Telephoto. Co-developed with Hasselblad in both sensor calibration and optical design, this telephoto camera meets Hasselblad’s exacting standards, delivering unparalleled detail and clarity in zoom shots.

IMG20250101141416

Beyond photography, Find X9 Series delivers exceptional video capabilities, supporting recording at up to 4K 120fps in Dolby Vision for incredibly smooth, cinematic footage. For professional users, the series introduces LOG recording with ACES support, perfect for seamless integration into a professional workflow. Paired with the cutting-edge telephotos and optimizations like Stage Mode and AI Sound Focus, Find X9 Series is perfect for capturing clear, high-quality concert shots and video, even from the back row.

Powering the series is the MediaTek Dimensity 9500 chipset, making Find X9 Series among the first equipped with this advanced 3nm platform. This is paired with OPPO’s advanced third-generation silicon-carbon battery technology, featuring capacities of 7025mAh in Find X9 and 7500mAh in Find X9 Pro to deliver up to two days of battery life at average usage.

Find X9 Series also features the latest ColorOS 16, setting a new standard for smoothness, intelligence, and connectivity. With the new Seamless Animation and Luminous Rendering Engine, ColorOS 16 delivers a silky-smooth experience all across the user interface, while OPPO AI continues to enhance the user experience with easy-to-use features like AI Portrait Glow. With extended connectivity, users can seamlessly connect with PCs, Macs, and other accessories.

OPPO partnered with Discovery Channel to launch the campaign Every Culture Finds Its Stage. It encouraged global communities to share their cultural stories through the Find X9 Series’ Hasselblad Telephoto camera. In 2025, OPPO and Discovery continued this journey with the second chapter of Culture in a Shot. The campaign spanned 15 countries, capturing vibrant festivals and traditions worldwide.

As it concludes, OPPO now highlights cultural performances on stage. Using the Find X9 Series, every detail is captured with clarity, near or far. And everyone is invited to zoom in on detail and celebrate cultural diversity.

Stay tuned to discover more about the OPPO Find X9 Series and ColorOS 16 at the upcoming global launch.
Hashtag: #OPPO #X9 #X9Pro #ColorOS16

The issuer is solely responsible for the content of this announcement.

About OPPO

OPPO is a leading global smart device brand. Since the launch of its first mobile phone – “Smiley Face” – in 2008, OPPO has been in relentless pursuit of the perfect synergy of aesthetic satisfaction and innovative technology. Today, OPPO provides a wide range of smart devices spearheaded by the Find and Reno series. Beyond devices, OPPO also provides its users with ColorOS operating system and internet services. OPPO has footprints in more than 70 countries and regions, with more than 40,000 employees dedicated to creating a better life for customers around the world.

Vice President of China Electronics Chamber of Commerce Peng Lihui Interviewed by Phoenix TV Americas, Emphatically Promoting the AIE Expo

By
Advertorial Desk
-

ZHUHAI, China, Oct. 16, 2025 /PRNewswire/ — Recently, Peng Lihui, Vice President and Secretary-General of the China Electronics Chamber of Commerce, was interviewed by Phoenix Television Americas, in which he gave a focused introduction of the Global Artificial Intelligence Machines and Electronics Expo (AIE) to be held from December 4 to 6, 2025, in the twin cities of Macao and Zhuhai. At present, the exhibition recruitment has achieved phased progress, and the industry response is enthusiastic.

 

Vice President of China Electronics Chamber of Commerce Peng Lihui Interviewed by Phoenix TV Americas, Emphatically Promoting the AIE Expo.

As of October 10, the expo has successfully invited 1,779 exhibitors, with nearly 800 confirmed participating enterprises. Renowned domestic companies including Lenovo, Haier, BOE, TCL, Skyworth, GAC, Midea, Leyard, Xiaomi, as well as international firms such as Tesla, Toshiba, Epson, Canon, Sony, Panasonic have all confirmed their participation. Together they will build a high-end platform for global intelligent technology showcasing and connection.

Booth allocation is being advanced efficiently in parallel: a total of 2,876 standard booths have been confirmed, reaching 95.9% of the target of 3,000 booths. The exhibition is planned to include six themed pavilions: “Intelligent Communication & IoT Pavilion”, “Intelligent Audiovisual & Metaverse Pavilion”, “Venture Capital & New Concept Pavilion”, “Intelligent Equipment & Industrial Internet Pavilion”, “Intelligent Transportation & Future Mobility Pavilion”, and “Smart Home & Health Technology Pavilion”, comprehensively covering cutting-edge fields such as intelligent manufacturing, artificial intelligence, and the digital economy.

Promotional efforts are proceeding simultaneously, with total online exposure surpassing 300 million impressions; social media interactions are active, and traffic to the official website continues climbing. With a strong momentum, AIE is becoming a high-end global platform for intelligent technology display and industry networking.

This edition of the expo, themed “Bay Area Intelligence, Globally Embraced”, adopts a “forum + exhibition” deeply integrated format, with a carefully planned “1 + 1 + 6 + N” series agenda. The main venue in Macao will host the opening ceremony and a high-level summit, and will launch a heavyweight industry white paper. A number of specialized sub-forums will focus on global industry hotspots such as AI applications, future mobility, and green computing power.

A global industry grand event is about to begin! The recruitment channels for professional visitors and buyers are officially open!

Sign up now to lock in your seat and connect with global industry resources at one click!

Visit the AIE official website (https://www.aie-expo.com/index/) to register now and get priority access to the expo manual, VIP matchmaking booking privileges, and a dedicated visitor guide. Seats are limited and available on a first-come, first-served basis!

Microban International Appoints Shermon McMillan as New President

By
Advertorial Desk
-

HUNTERSVILLE, N.C., Oct. 16, 2025 /PRNewswire/ — Microban International, the global leader in antimicrobial and odor control solutions, today announced the appointment of Shermon McMillan as its new president. A seasoned global executive with a proven record of driving growth at Fortune 500 companies, McMillan will guide Microban strategy, operations and innovation pipeline toward sustainable growth.

Shermon McMillan will oversee Microban's operations, strategy and innovation pipeline to drive sustainable growth.
Shermon McMillan will oversee Microban’s operations, strategy and innovation pipeline to drive sustainable growth.

“Shermon McMillan is a strategic and experienced leader who understands Microban’s goals and how to bring them to fruition,” said Scott Beal, CEO at Barr Brands International, parent company of Microban. “We are confident he will help us elevate the Microban brand and maintain a leadership position in the global marketplace.”

As president, McMillan will focus on building the Microban brand and growing the company’s reputation as the most trusted name in product protection. His leadership will put customers at the center, prioritize the execution of relevant innovation, and build brand equity. By combining customer centrality, innovation and brand building, McMillan will ensure Microban continues to deliver value for both industry partners and end-users.

“Microban has experienced remarkable growth over its four-decade history, and I look forward to helping drive our next phase of global growth and innovation,” said Shermon. “With the help of our talented team, Microban will be the most-recognized leader in product protection.”

McMillan brings a wealth of experience across consumer healthcare and household categories. Most recently, he served as vice president and general manager at The Clorox Company, where he successfully turned around the vitamins, minerals and supplements business, delivering first-time profitability and managing its successful divestiture. Prior to that, McMillan held senior leadership roles at Sanofi Consumer Healthcare, including global vice president, overseeing a multibillion-dollar global allergy, cold and cough portfolio across over 100 countries.

About Microban International

Part of Barr Brands International, Microban International is home to the most trusted and well-known global brands in the antimicrobial, odor control and sanitization/disinfection markets: Microban® and Ultra-Fresh®. Our organization has experienced over 100 collective years of growth and has revolutionized the industry. As the global leader, our proactive systems keep products cleaner and control odors better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products worldwide. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina and operates in North America, Europe and Asia-Pacific. For more information, please visit www.microban.com.

 

1...1,9511,9521,953...6,308Page 1,952 of 6,308